<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Lung cancer is still the leading cancer-related cause of death with a high incidence rate in the whole world. Treatment options – surgery, radiotherapy, and chemotherapy, depending on the stage of the disease. During the last decade, many molecular alterations were discovered that led to impressive changes in treatment. Personalized approaches, including target therapies with specific inhibitor drugs, became a part of the standard therapies. This article reviews current molecular biomarkers used in clinical practice to treat lung cancer patients.</p></abstract>

Lung cancer is still the leading cancer-related cause of death with a high incidence rate in the whole world. Treatment options – surgery, radiotherapy, and chemotherapy, depending on the stage of the disease. During the last decade, many molecular alterations were discovered that led to impressive changes in treatment. Personalized approaches, including target therapies with specific inhibitor drugs, became a part of the standard therapies. This article reviews current molecular biomarkers used in clinical practice to treat lung cancer patients.

Molecular Diagnosis of Lung Cancer

University Scientific Research Laboratory

Journal of Biomedical and Clinical Research

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"Molecular Diagnosis of Lung Cancer"}

Lung cancer is still the leading cancer-related cause of death with a high incidence rate in the whole world. Treatment options – surgery, radiotherapy, and...

Molecular Diagnosis of Lung Cancer

Publié en ligne: 30 juin 2018

Pages: 98 - 103

Reçu: 16 janv. 2018

Accepté: 27 févr. 2018

DOI: https://doi.org/10.1515/jbcr-2017-0016

Mots clés
molecular biomarkers, lung cancer, targeted therapies

© 2017 Savelina L. Popovska et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Molecular Diagnosis of Lung Cancer

Publié en ligne: 30 juin 2018

Pages: 98 - 103

Reçu: 16 janv. 2018

Accepté: 27 févr. 2018

DOI: https://doi.org/10.1515/jbcr-2017-0016

Mots clésmolecular biomarkers, lung cancer, targeted therapies

© 2017 Savelina L. Popovska et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Mots clés
molecular biomarkers, lung cancer, targeted therapies